Halozyme COO Cortney Caudill Departs Amid Senior Management Structure Update
HALO sits 51% above its 52-week low of $52.72.
Summary
Halozyme Therapeutics announced the departure of Cortney Caudill as Senior Vice President and Chief Operating Officer, as part of an update to its senior management structure.
Key Events · Executive and Board Changes · HALO
-
Chief Operating Officer Departs
Cortney Caudill has departed from her role as Senior Vice President, Chief Operating Officer, effective June 30, 2026.
-
Senior Management Structure Update
The company announced this departure as part of an update to its senior management structure, following a recent CFO appointment in April.
Analysis · HALO · Life Sciences
The departure of a Chief Operating Officer is a significant change in a company's leadership, especially for a large life sciences firm like Halozyme. While the filing does not specify the reason for Ms. Caudill's departure, it notes an "update to its senior management structure." This follows the recent appointment of a new CFO in April, suggesting a broader organizational realignment. Investors will be looking for further details on the new management structure and any potential replacement for the COO role to understand the strategic direction.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HALO was trading at $79.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4B. The 52-week trading range was $52.72 to $82.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.